Therefore, we found that Ripretinib is associated with a range of dermatologic AEs, probably because of malignant cells and normal skin mucous membrane tissue Shared between signaling pathways, some target molecules (i.e., EGFR] and vascular EGFR [VEGFR]) are also present in the skin (Deutsch et al., 2020; Reyes-Habito and Roh, 2014; American Cancer Society web site, 2024). The gene discussed is EGFR; the disease is cancer.